Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A review and meta

One possible side effect of thrombopoietin receptor agonists in immune thrombocytopenia is thrombosis. Our aim is to systematically review whether patients with ITP that were treated with a TPO-RA have an increased risk for thrombosis as compared to ITP patients without TPO-RA. Patients in the intervention group were required to receive TPO-RA therapy. The primary outcome was the incidence of thromboembolic events. Eleven studies were included in the pooled analysis. More thromboembolic events were noted in the TPO-RA group than in the control group: 25 compared to 4. Ten out of 11 studies showed a relative risk greater than 1. However, none of these individual risk ratios was statistically significant. The meta-analysis showed a RR of 1.82 [95 % CI 0.78-4.24]. Our findings indicate there is a non-significant higher chance of thrombosis in ITP patients with TPORA treatments versus ITP patients without TPO-RA treatment.

Automated summary

This study aimed to review whether patients with immune thrombocytopenia (ITP) treated with thrombopoietin receptor agonists (TPO-RA) have a higher risk of thrombosis compared to ITP patients without TPO-RA treatment. The analysis included 11 studies, and although more thromboembolic events were observed in the TPO-RA group, the individual risk ratios were not statistically significant. The meta-analysis showed a non-significant higher chance of thrombosis in ITP patients with TPO-RA treatment.